Skip to content

Study · Randomized controlled trial · n = 31 · 2016

4 results

Oxytocin to modulate emotional processing in schizophrenia: A randomized, double-blind, cross-over clinical trial.

Brambilla M, Cotelli M, Manenti R, Dagani J, Sisti D, Rocchi M, Balestrieri M, Pini S, Raimondi S, Saviotti FM, Scocco P, de Girolamo G

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology12 Aug 2016Cited by 23 (Europe PMC)

PMID27527256 (opens in a new tab)DOI10.1016/j.euroneuro.2016.08.001 (opens in a new tab)PepBankPUB-27527256
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with schizophrenia, oxytocin improved performance on the MSCEIT Understanding Emotion branch compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin improved performance on an emotion understanding test compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseMSCEIT Branch 3 Understanding Emotion
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    Dose not stated · intranasal · four monthsAs given in this study (human).

    Source sentences

    Summary
    We found that oxytocin improved performance on MSCEIT compared to placebo in Branch 3-Understanding Emotion (p-value=0.004; Cohen׳s d=1.12).
    2 context sentences
    Summary · context
    The aim of this study was to examine the effects of four months of treatment with intranasal oxytocin, in 31 patients with schizophrenia, on distinct aspects of social cognition.
    Summary · context
    This was assessed using standardized and experimental tests in a randomized, double-blind, placebo-controlled, cross-over trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with schizophrenia, oxytocin significantly reduced reaction times for facial affect recognition in the Emotional Priming Paradigm.

    In plain wordsIn people with schizophrenia, oxytocin made recognition of facial emotions faster in a computer task.

    Peptide
    Oxytocin
    Outcome
    DecreaseReaction time for facial affect recognition in the Emotional Priming Paradigm
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    Dose not stated · intranasal · four monthsAs given in this study (human).

    Source sentences

    Summary
    In the EPP task, we observed a significant reduction of reaction times for facial affect recognition (p-value=0.021; Cohen׳s d=0.88).
    2 context sentences
    Summary · context
    The aim of this study was to examine the effects of four months of treatment with intranasal oxytocin, in 31 patients with schizophrenia, on distinct aspects of social cognition.
    Summary · context
    This was assessed using standardized and experimental tests in a randomized, double-blind, placebo-controlled, cross-over trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with schizophrenia, oxytocin had no effect on implicit priming.

    In plain wordsIn people with schizophrenia, oxytocin had no effect on implicit emotional priming.

    Peptide
    Oxytocin
    Outcome
    No significant changeImplicit priming
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    Dose not stated · intranasal · four monthsAs given in this study (human).

    Source sentences

    Summary
    No effects were found for implicit priming
    2 context sentences
    Summary · context
    The aim of this study was to examine the effects of four months of treatment with intranasal oxytocin, in 31 patients with schizophrenia, on distinct aspects of social cognition.
    Summary · context
    This was assessed using standardized and experimental tests in a randomized, double-blind, placebo-controlled, cross-over trial.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with schizophrenia, oxytocin had no effect on theory of mind abilities.

    In plain wordsIn people with schizophrenia, oxytocin had no effect on the ability to understand what others think.

    Peptide
    Oxytocin
    Outcome
    No significant changeTheory of mind abilities
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    Dose not stated · intranasal · four monthsAs given in this study (human).

    Source sentences

    Summary
    theory of mind abilities.
    2 context sentences
    Summary · context
    The aim of this study was to examine the effects of four months of treatment with intranasal oxytocin, in 31 patients with schizophrenia, on distinct aspects of social cognition.
    Summary · context
    This was assessed using standardized and experimental tests in a randomized, double-blind, placebo-controlled, cross-over trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.